Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -184.12 Million USD | -30.56% |
| 2022 | -141.03 Million USD | -16.6% |
| 2021 | -120.95 Million USD | -59.97% |
| 2020 | -75.61 Million USD | -18.98% |
| 2019 | -63.55 Million USD | -135.23% |
| 2018 | -27.01 Million USD | 3.22% |
| 2017 | -27.91 Million USD | 5.49% |
| 2016 | -29.53 Million USD | -64310.87% |
| 2015 | 46 Thousand USD | 100.13% |
| 2014 | -35.67 Million USD | 7.06% |
| 2013 | -38.37 Million USD | 44.28% |
| 2012 | -68.88 Million USD | 28.88% |
| 2011 | -96.85 Million USD | 13.04% |
| 2010 | -111.37 Million USD | -58.69% |
| 2009 | -70.18 Million USD | -13.16% |
| 2008 | -62.02 Million USD | -69.01% |
| 2007 | -36.69 Million USD | -17.0% |
| 2006 | -31.36 Million USD | 6.45% |
| 2005 | -33.52 Million USD | 58.3% |
| 2004 | -80.4 Million USD | -169.07% |
| 2003 | -29.88 Million USD | 11.87% |
| 2002 | -33.9 Million USD | 19.41% |
| 2001 | -42.07 Million USD | 8.2% |
| 2000 | -45.83 Million USD | 1.22% |
| 1999 | -46.4 Million USD | -329.63% |
| 1998 | -10.8 Million USD | -12.5% |
| 1997 | -9.6 Million USD | 10.28% |
| 1996 | -10.7 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -67.38 Million USD | -21.65% |
| 2024 Q1 | -55.39 Million USD | -6.57% |
| 2023 Q3 | -44.8 Million USD | 8.98% |
| 2023 Q1 | -38.07 Million USD | 10.22% |
| 2023 Q4 | -51.97 Million USD | -16.0% |
| 2023 Q2 | -49.22 Million USD | -29.29% |
| 2023 FY | -184.12 Million USD | -30.56% |
| 2022 FY | -141.03 Million USD | -16.6% |
| 2022 Q1 | -31.52 Million USD | 1.55% |
| 2022 Q2 | -28.25 Million USD | 10.35% |
| 2022 Q3 | -40.82 Million USD | -44.48% |
| 2022 Q4 | -42.4 Million USD | -3.87% |
| 2021 Q2 | -29.57 Million USD | -6.29% |
| 2021 Q1 | -27.82 Million USD | -16.97% |
| 2021 Q3 | -26.69 Million USD | 9.73% |
| 2021 FY | -120.95 Million USD | -59.97% |
| 2021 Q4 | -32.01 Million USD | -19.93% |
| 2020 Q3 | -19.65 Million USD | -24.18% |
| 2020 Q1 | -16.35 Million USD | 43.74% |
| 2020 FY | -75.61 Million USD | -18.98% |
| 2020 Q2 | -15.82 Million USD | 3.25% |
| 2020 Q4 | -23.78 Million USD | -21.05% |
| 2019 Q3 | -15.18 Million USD | -6.61% |
| 2019 FY | -63.55 Million USD | -135.23% |
| 2019 Q1 | -10.05 Million USD | -37.79% |
| 2019 Q2 | -14.23 Million USD | -41.55% |
| 2019 Q4 | -29.07 Million USD | -91.5% |
| 2018 Q1 | -7.18 Million USD | 3.27% |
| 2018 Q2 | -6.93 Million USD | 3.51% |
| 2018 Q3 | -5.59 Million USD | 19.28% |
| 2018 Q4 | -7.3 Million USD | -30.43% |
| 2018 FY | -27.01 Million USD | 3.22% |
| 2017 FY | -27.91 Million USD | 5.49% |
| 2017 Q1 | -7.18 Million USD | 15.31% |
| 2017 Q3 | -6.89 Million USD | -7.71% |
| 2017 Q2 | -6.4 Million USD | 10.83% |
| 2017 Q4 | -7.42 Million USD | -7.68% |
| 2016 Q3 | -3.57 Million USD | 58.6% |
| 2016 Q1 | -8.84 Million USD | -4.42% |
| 2016 Q4 | -8.48 Million USD | -137.19% |
| 2016 FY | -29.53 Million USD | -64310.87% |
| 2016 Q2 | -8.63 Million USD | 2.32% |
| 2015 Q1 | -9.31 Million USD | -4.11% |
| 2015 FY | 46 Thousand USD | 100.13% |
| 2015 Q3 | 27.18 Million USD | 390.56% |
| 2015 Q2 | -9.35 Million USD | -0.44% |
| 2015 Q4 | -8.46 Million USD | -131.15% |
| 2014 FY | -35.67 Million USD | 7.06% |
| 2014 Q4 | -8.94 Million USD | 6.3% |
| 2014 Q3 | -9.54 Million USD | -9.33% |
| 2014 Q1 | -8.44 Million USD | 9.06% |
| 2014 Q2 | -8.73 Million USD | -3.48% |
| 2013 Q2 | -8.94 Million USD | 24.8% |
| 2013 Q1 | -11.89 Million USD | 25.0% |
| 2013 FY | -38.37 Million USD | 44.28% |
| 2013 Q4 | -9.28 Million USD | -12.44% |
| 2013 Q3 | -8.25 Million USD | 7.75% |
| 2012 Q2 | -18.32 Million USD | 2.2% |
| 2012 Q3 | -15.95 Million USD | 12.95% |
| 2012 Q4 | -15.86 Million USD | 0.56% |
| 2012 FY | -68.88 Million USD | 28.88% |
| 2012 Q1 | -18.73 Million USD | 41.17% |
| 2011 Q2 | -21.08 Million USD | 13.53% |
| 2011 FY | -96.85 Million USD | 13.04% |
| 2011 Q4 | -31.85 Million USD | -63.17% |
| 2011 Q1 | -24.38 Million USD | 58.91% |
| 2011 Q3 | -19.52 Million USD | 7.43% |
| 2010 Q1 | -16.64 Million USD | 9.52% |
| 2010 FY | -111.37 Million USD | -58.69% |
| 2010 Q4 | -59.36 Million USD | -223.6% |
| 2010 Q3 | -18.34 Million USD | -7.71% |
| 2010 Q2 | -17.03 Million USD | -2.35% |
| 2009 Q4 | -18.39 Million USD | -20.8% |
| 2009 Q2 | -19.75 Million USD | -17.53% |
| 2009 Q1 | -16.81 Million USD | 4.66% |
| 2009 FY | -70.18 Million USD | -13.16% |
| 2009 Q3 | -15.22 Million USD | 22.95% |
| 2008 Q4 | -17.63 Million USD | -2.8% |
| 2008 Q2 | -13.56 Million USD | 0.8% |
| 2008 FY | -62.02 Million USD | -69.01% |
| 2008 Q3 | -17.15 Million USD | -26.45% |
| 2008 Q1 | -13.67 Million USD | -23.8% |
| 2007 Q2 | -13.98 Million USD | -1298.37% |
| 2007 Q4 | -11.04 Million USD | 13.94% |
| 2007 FY | -36.69 Million USD | -17.0% |
| 2007 Q1 | 1.16 Million USD | 135.79% |
| 2007 Q3 | -12.83 Million USD | 8.23% |
| 2006 Q4 | -3.26 Million USD | 66.85% |
| 2006 FY | -31.36 Million USD | 6.45% |
| 2006 Q3 | -9.83 Million USD | -6.27% |
| 2006 Q2 | -9.25 Million USD | -2.74% |
| 2006 Q1 | -9.01 Million USD | -1.28% |
| 2005 Q2 | -3.08 Million USD | 68.19% |
| 2005 Q4 | -8.89 Million USD | 25.0% |
| 2005 FY | -33.52 Million USD | 58.3% |
| 2005 Q1 | -9.68 Million USD | -2.25% |
| 2005 Q3 | -11.86 Million USD | -284.88% |
| 2004 Q2 | -8.94 Million USD | 82.69% |
| 2004 Q3 | -10.3 Million USD | -15.17% |
| 2004 Q1 | -51.68 Million USD | -584.0% |
| 2004 FY | -80.4 Million USD | -169.07% |
| 2004 Q4 | -9.47 Million USD | 8.03% |
| 2003 Q3 | -5.1 Million USD | 45.02% |
| 2003 Q1 | -7.93 Million USD | -9.72% |
| 2003 Q2 | -9.28 Million USD | -17.1% |
| 2003 Q4 | -7.55 Million USD | -47.95% |
| 2003 FY | -29.88 Million USD | 11.87% |
| 2002 Q2 | -9 Million USD | 14.0% |
| 2002 Q3 | -7.19 Million USD | 20.12% |
| 2002 Q4 | -7.22 Million USD | -0.46% |
| 2002 Q1 | -10.47 Million USD | 46.13% |
| 2002 FY | -33.9 Million USD | 19.41% |
| 2001 Q2 | -6.08 Million USD | 18.22% |
| 2001 FY | -42.07 Million USD | 8.2% |
| 2001 Q4 | -19.44 Million USD | -113.39% |
| 2001 Q3 | -9.11 Million USD | -49.84% |
| 2001 Q1 | -7.43 Million USD | 53.3% |
| 2000 Q1 | -6.59 Million USD | 18.59% |
| 2000 Q4 | -15.92 Million USD | -223.13% |
| 2000 Q3 | -4.92 Million USD | 70.13% |
| 2000 FY | -45.83 Million USD | 1.22% |
| 2000 Q2 | -16.49 Million USD | -150.2% |
| 1999 Q3 | -6.9 Million USD | 75.36% |
| 1999 Q2 | -28 Million USD | -748.48% |
| 1999 FY | -46.4 Million USD | -329.63% |
| 1999 Q1 | -3.3 Million USD | 10.81% |
| 1999 Q4 | -8.1 Million USD | -17.39% |
| 1998 Q3 | -2.8 Million USD | -16.67% |
| 1998 Q4 | -3.7 Million USD | -32.14% |
| 1998 Q2 | -2.4 Million USD | -26.32% |
| 1998 Q1 | -1.9 Million USD | -35.71% |
| 1998 FY | -10.8 Million USD | -12.5% |
| 1997 Q1 | -4.4 Million USD | -41.94% |
| 1997 Q4 | -1.4 Million USD | 30.0% |
| 1997 FY | -9.6 Million USD | 10.28% |
| 1997 Q3 | -2 Million USD | -11.11% |
| 1997 Q2 | -1.8 Million USD | 59.09% |
| 1996 Q2 | -2.5 Million USD | -4.17% |
| 1996 FY | -10.7 Million USD | 0.0% |
| 1996 Q4 | -3.1 Million USD | -14.81% |
| 1996 Q3 | -2.7 Million USD | -8.0% |
| 1996 Q1 | -2.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -20.172% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2781.938% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 14091.413% |
| Perrigo Company plc | -12.7 Million USD | -1349.819% |
| Illumina, Inc. | -1.16 Billion USD | 84.141% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 103.071% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 58.533% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.868% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 113.559% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -66.542% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 104.657% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -361.934% |
| Waters Corporation | 642.23 Million USD | 128.67% |
| Biogen Inc. | 1.16 Billion USD | 115.858% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 28.586% |
| Evolus, Inc. | -61.68 Million USD | -198.496% |
| Adicet Bio, Inc. | -142.65 Million USD | -29.069% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -55.364% |
| bluebird bio, Inc. | -211.91 Million USD | 13.112% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 12.005% |
| FibroGen, Inc. | -284.23 Million USD | 35.219% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 114.849% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -312.81% |
| Homology Medicines, Inc. | -53.74 Million USD | -242.606% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 58.176% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -21.469% |
| Myriad Genetics, Inc. | -112 Million USD | -64.399% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -114.363% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 61.735% |
| Zoetis Inc. | 2.34 Billion USD | 107.855% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -239.793% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 123.343% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 209.831% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 105.087% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -336.33% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 49.731% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 33.318% |
| Verastem, Inc. | -87.36 Million USD | -110.751% |
| Nektar Therapeutics | -276.05 Million USD | 33.301% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 23.036% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -108.098% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 65.646% |
| OPKO Health, Inc. | -188.86 Million USD | 2.508% |
| Exelixis, Inc. | 207.76 Million USD | 188.623% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 173.739% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 273.476% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -287.595% |
| uniQure N.V. | -308.47 Million USD | 40.311% |
| Imunon, Inc. | -19.51 Million USD | -843.516% |
| Blueprint Medicines Corporation | -506.98 Million USD | 63.682% |
| Insmed Incorporated | -749.56 Million USD | 75.436% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 165.387% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 47.704% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1553.022% |
| Incyte Corporation | 597.59 Million USD | 130.811% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 75.789% |